Latest Sedatives Stories
Findings could lead to new antidotes, treatments.
New research shows that frequent use of ketamine - a drug popular with clubbers - is being linked with memory problems.
The first ever large-scale, longitudinal study of ketamine users has been published online today in the journal Addiction.
RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for IntermezzoÂ® (zolpidem tartrate sublingual tablet).
US drug labels often omit key information about a medicineâ€™s effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine.
REDWOOD CITY, Calif., Oct. 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam.
Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide. However, intravenous (IV) ketamine, a drug previously used as an anesthetic, has shown rapid antidepressant effects in early trials.
SOMERSET, N.J., Sept. 8 /PRNewswire/ -- Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States.
RICHMOND, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.
BEVERLY HILLS, Calif., Aug.